The FDA expanded the Emergency Use Authorization for Lilly’s bamlanivimab and etesevimab administered together to include certain high-risk pediatric patients from birth to <12 years old, as well as post-exposure prophylaxis.   The expanded authorization is based on safety and efficacy data of pediatric and infant patients in BLAZE-1, a phase 2/3 clinical trial studying bamlanivimab and etesevimab administered together for the treatment of mild to moderate COVID-19 and who are at high risk ...